复发难治弥漫大B细胞淋巴瘤患者接受polatuzumab vedotin同情用药一例并文献复习

目的:探讨polatuzumab vedotin（pola）治疗复发难治弥漫大B细胞淋巴瘤（DLBCL）患者的效果和安全性。方法:回顾性分析2016年5月江苏省肿瘤医院收治的1例多次接受治疗的DLBCL患者的临床资料，并进行文献复习。结果:该患者为57岁男性，2016年5月诊断为DLBCL，从2016年6月起接受包括抗CD20单抗联合化疗、仅化疗以及嵌合抗原受体T细胞（CAR-T）等在内的四线治疗，但治疗后均复发或进展。于2019年12月起接受pola联合利妥昔单抗6个疗程治疗，治疗过程中无非预期不良反应。治疗结束后临床疗效评价为完全缓解。随访截至2021年1月，患者无进展生存时间超过13个月。结论:pola在复发难治DLBCL患者的治疗中初步显示了良好的有效性和安全性。

Compassionate use of polatuzumab vedotin in patients with relapsed/refractory diffuse large B-cell lymphoma: report of one case and review of literature

Objective:To investigate the efficacy and safety of polatuzumab vedotin (pola) in treatment of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).Methods:The clinical data of 1 DLBCL patient receiving multiple treatments in Jiangsu Cancer Hospital in May 2016 were retrospectively analyzed, and the related literature was reviewed.Results:The patient, a 57-year-old male, was diagnosed with DLBCL in May 2016. Since June 2016, he had received treatments with four lines including anti-CD20 monoclonal antibody combined with chemotherapy, chemotherapy only and chimeric antigen receptor T cell (CAR-T). However, the disease relapsed or progressed after all treatments. Therefore, the patient had received 6 cycles of pola combined with rituximab since December 2019. Unexpected adverse events were not found during the treatment. The evaluation of clinical efficacy was complete remission after the end of treatment. The progression-free survival time was more than 13 months with follow-up until January 2021.Conclusion:Pola initially shows good efficacy and safety in treatment of patients with relapsed/refractory DLBCL.